Decoding the intricacies of the mast cell compartment.
Age Factors
Biomarkers
Biopsy
Combined Modality Therapy
Diagnosis, Differential
Disease Management
Disease Susceptibility
/ immunology
Genetic Predisposition to Disease
Homeostasis
Humans
Immunophenotyping
Mast Cells
/ cytology
Mastocytosis
/ diagnosis
Molecular Diagnostic Techniques
Phenotype
Prognosis
Treatment Outcome
activation
anaphylaxis
mast cells
mastocytosis
mediators
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
pubmed:
11
8
2021
medline:
15
2
2022
entrez:
10
8
2021
Statut:
ppublish
Résumé
Historically, understanding of the human mast cell (MC) compartment has lagged behind the appreciation of other cell lineages. MCs exist in vascularised tissues but do not under normal circumstances circulate in blood, and there has been no pharmacological agent identified that totally and selectively inhibits human MC function. There are no substantiated accounts of an apparently healthy individual who is severely lacking in MCs. Thus, some of the approaches employed to understand the function of a specific immune cell are not available to the MC biologist. The disease categories that have provided the greatest insight into MC biology have been monoclonal and IgE-mediated MC disorders. This has led to the categorisation of MC diseases as intrinsic or extrinsic to the MC compartment and to the recognition of the role of mediators in MC activation disorders. Mastocytosis as a clonal disorder not only impacts the MC compartment through changes intrinsic to the MC, but also by the effects of episodes of significant release of MC mediators. The availability of newer therapeutic approaches developed to treat monoclonal MC disorders offer insights into how to more selectively approach management of MC centric diseases.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
304-315Informations de copyright
© Published 2021. This article is a U.S. Government work and is in the public domain in the USA.
Références
IraniAA, SchechterNM, CraigSS, DeBloisG, SchwartzLB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA. 1986;83(12):4464-8.
IraniAM, SchwartzLB. Human mast cell heterogeneity. Allergy Proc. 1994;15(6):303-8.
BraddingP, SaitoH. Biology of mast cells and their mediators. Middleton's allergy: principles and practice. 1. 8th ed. Amsterdam: Elsevier Health Sciences; 2014.
DvorakAM, SchleimerRP, LichtensteinLM. Human mast cells synthesize new granules during recovery from degranulation. In vitro studies with mast cells purified from human lungs. Blood. 1988;71(1):76-85.
WellerK, FoitzikK, PausR, SyskaW, MaurerM, WellerK, et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20(13):2366-8.
HeissigB, RafiiS, AkiyamaH, OhkiY, SatoY, RafaelT, et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med. 2005;202(6):739-50.
EchtenacherB, MannelDN, HultnerL. Critical protective role of mast cells in a model of acute septic peritonitis. Nature. 1996;381(6577):75-7.
AkinC, ValentP, MetcalfeDD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099-1104.e4.
ValentP, AkinC, ArockM, BrockowK, ButterfieldJH, CarterMC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-25.
ValentP, BonadonnaP, HartmannK, Broesby-OlsenS, BrockowK, ButterfieldJ, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019;180(1):44-51.
SalaA, FolcoG, MurphyRC. Transcellular biosynthesis of eicosanoids. Pharmacol Rep. 2010;62(3):503-10.
ValentP, AkinC, BonadonnaP, HartmannK, BrockowK, NiedoszytkoM, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.e1.
ValentP, AkinC, NedoszytkoB, BonadonnaP, HartmannK, NiedoszytkoM, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. Int J Mol Sci. 2020;21(23):9030.
ValentP, AkinC, MetcalfeDD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-7.
BodemerC, HermineO, PalmériniF, YangY, Grandpeix-GuyodoC, LeventhalPS, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804-15.
CastellsM, AustenKF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127(2):147-52.
McFarlinKE, KruesiMJ, MetcalfeDD. A preliminary assessment of behavioral problems in children with mastocytosis. Int J Psychiatry Med. 1991;21(3):281-9.
GalenBT, RoseMG. Darier's sign in mastocytosis. Blood. 2014;123(8):1127.
CarterMC, ClaytonST, KomarowHD, BrittainEH, ScottLM, CantaveD, et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol. 2015;136(6):1673-9.
LangeM, NiedoszytkoM, RenkeJ, GlenJ, NedoszytkoB. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol. 2013;27(1):97-102.
MéniC, BruneauJ, Georgin-LavialleS, Le Saché de PeufeilhouxL, DamajG, Hadj-RabiaS, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172(3):642-51.
AkinC, MetcalfeDD. Systemic mastocytosis. Annu Rev Med. 2004;55:419-32.
HartmannK, EscribanoL, GrattanC, BrockowK, CarterMC, Alvarez-TwoseI, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35-45.
IraniAM, SchwartzLB. Mast cell heterogeneity. Clin Exp Allergy. 1989;19(2):143-55.
IraniAA, GarrigaMM, MetcalfeDD, SchwartzLB. Mast cells in cutaneous mastocytosis: accumulation of the MCTC type. Clin Exp Allergy. 1990;20(1):53-8.
WolffK, KomarM, PetzelbauerP. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25(7):519-28.
GarrigaMM, FriedmanMM, MetcalfeDD. A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol. 1988;82(3 Pt 1):425-32.
MeniC, Georgin-LavialleS, SacheLE, dePeufeilhouxL, JaisJP, Hadj-RabiaS, et al. Paediatric mastocytosis: long-term follow-up of 53 patients with whole sequencing of KIT. A prospective study. Br J Dermatol. 2018;179(4):925-32.
MaY, ZengS, MetcalfeDD, AkinC, DimitrijevicS, ButterfieldJH, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741-4.
CarterMC, BaiY, Ruiz-EstevesKN, ScottLM, CantaveD, BolanH, et al. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. Br J Haematol. 2018;183(5):775-82.
SperrWR, KundiM, Alvarez-TwoseI, van AnrooijB, Oude ElberinkJNG, GorskaA, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019;6(12):e638-49.
JawharM, SchwaabJ, Álvarez-TwoseI, ShoumariyehK, NaumannN, LübkeJ, et al. MARS: mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37(31):2846-56.
CarterMC, MetcalfeDD. Paediatric mastocytosis. Arch Dis Child. 2002;86(5):315-9.
LangeM, HartmannK, CarterMC, SiebenhaarF, Alvarez-TwoseI, TorradoI, et al. Molecular background, clinical features and management of pediatric mastocytosis: status 2021. Int J Mol Sci. 2021;22(5):2586.
WiechersT, RabenhorstA, SchickT, PreussnerLM, FörsterA, ValentP, et al. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136(6):1581-90 e3.
Álvarez-TwoseI, González de OlanoD, Sánchez-MuñozL, MatitoA, Esteban-LópezMI, VegaA, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125(6):1269-1278.e2.
BonadonnaP, PerbelliniO, PassalacquaG, CarusoB, ColarossiS, Dal FiorD, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123(3):680-6.
LimK-H, TefferiA, LashoTL, FinkeC, PatnaikM, ButterfieldJH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727-36.
Álvarez-TwoseI, Jara-AcevedoM, MorgadoJM, García-MonteroA, Sánchez-MuñozL, TeodósioC, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137(1):168-178.e1.
MetcalfeDD, GotlibJ. Systemic mastocytosis. In: GreerJ, ArberDA, ApplebaumFR, RodgersGM, MeansRT, DispenzieriA, et al., Wintrobe's clinical hematology, 14th ed. Philadelphia: Wolters Kluwer; 2019. p. 1793-808.
ValentP, AkinC, HartmannK, NilssonG, ReiterA, HermineO, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77(6):1261-70.
ValentP, AkinC, EscribanoL, FödingerM, HartmannK, BrockowK, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435-53.
AkinC, ValentP, EscribanoL. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep. 2006;6(4):282-8.
ShahS, PardananiA, ElalaYC, LashoTL, PatnaikMM, ReichardKK, et al. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. Am J Hematol. 2018;93(12):1461-6.
NedoszytkoB, Sobalska-KwapisM, StrapagielD, LangeM, GórskaA, ElberinkJNGO, et al. Results from a Genome-Wide Association Study (GWAS) in mastocytosis reveal new gene polymorphisms associated with WHO subgroups. Int J Mol Sci. 2020;21(15):5506.
ReiterA, GeorgeTI, GotlibJ. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020;135(16):1365-76.
Muñoz-GonzálezJI, Álvarez-TwoseI, Jara-AcevedoM, HenriquesA, ViñasE, PrietoC, et al. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood. 2019;134(5):456-68.
PardananiA, ShahS, MannelliF, ElalaYC, GuglielmelliP, LashoTL, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018;2(21):2964-72.
LimKH, PardananiA, ButterfieldJH, LiCY, TefferiA. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009;84(12):790-4.
UstunC, DeRemerDL, AkinC. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res. 2011;35(9):1143-52.
WorobecAS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am. 2000;14(3):659-87, vii.
UstunC, ReiterA, ScottBL, NakamuraR, DamajG, KreilS, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32(29):3264-74.
NakamuraR, ChakrabartiS, AkinC, RobynJ, BahceciE, GreeneA, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant. 2006;37(4):353-8.
HennessyB, GilesF, CortesJ, O'BrienS, FerrajoliA, OssaG, et al. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol. 2004;77(3):209-14.
PrzepiorkaD, GiraltS, KhouriI, ChamplinR, Bueso-RamosC. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol. 1998;57(1):24-8.
Ronnov-JessenD, Lovgreen NielsenP, HornT. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant. 1991;8(5):413-5.
Van HoofA, CrielA, LouwagieA, VanvuchelenJ. Cutaneous mastocytosis after autologous bone marrow transplantation. Bone Marrow Transplant. 1991;8(2):151-3.
CarterMC, DesaiA, KomarowHD, BaiY, ClaytonST, ClarkAS, et al. A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. J Allergy Clin Immunol. 2018;141(1):180-188.e3.
SampsonHA, Muñoz-FurlongA, CampbellRL, AdkinsonNF, BockSA, BranumA, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-7.
BrownGA, KempSF, LiebermanPL. Anaphylaxis. In: AtkinsonNF JWF, C.E.R., BochnerBS, BurksAW, BusseW, HolgateS, LemanskeRF, O'HehireRE, editors. Allergy: Principles & practice. 8th ed. Amsterdam: Elsevier; 2014. p. 1237-59.
TurnerPJ, WormM, AnsoteguiIJ, El-GamalY, RivasMF, FinemanS, et al. Time to revisit the definition and clinical criteria for anaphylaxis?World Allergy Organ J. 2019;12(10):100066.
AkinC, ScottLM, KocabasCN, Kushnir-SukhovN, BrittainE, NoelP, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007;110(7):2331-3.
GulenT, HagglundH, DahlenB, NilssonG. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clin Exp Allergy. 2014;44(1):121-9.
GulenT, HagglundH, SanderB, DahlenB, NilssonG. The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy. 2014;44(9):1179-87.
DemirturkM, GelincikA, ColakogluB, DalM, BuyukozturkS. Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol. 2012;39(6):552-4.
JonesJD, MarneySRJr, FahrenholzJM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol. 2008;101(5):550-1.
PittTJ, CisnerosN, KalicinskyC, BeckerAB. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol. 2010;126(2):415-6. author reply 6.
WarrierP, CasaleTB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol. 2009;102(3):257-8.
Broesby-OlsenS, VestergaardH, MortzCG, JensenB, HavelundT, HermannAP, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy. 2018;73(1):230-8.
ConstantineGM, BresslerPB, PetroniD, MetcalfeDD, CarterMC. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. J Allergy Clin Immunol Pract. 2019;7(4):1314-6.
LyonsJJ, YuX, HughesJD, LeQT, JamilA, BaiY, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564-9.
FellingerC, HemmerW, WohrlS, Sesztak-GreineckerG, JarischR, WantkeF. Clinical characteristics and risk profile of patients with elevated baseline serum tryptase. Allergol Immunopathol. 2014;42(6):544-52.
Gonzalez-QuintelaA, VizcainoL, GudeF, ReyJ, MeijideL, Fernandez-MerinoC, et al. Factors influencing serum total tryptase concentrations in a general adult population. Clin Chem Lab Med. 2010;48(5):701-6.
GiannettiMP, AkinC, HufdhiR, HamiltonMJ, WellerE, vanAnrooijB, et al. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology. J Allergy Clin Immunol. 2021;147(4):1497-501.
HamiltonMJ, ZhaoM, GiannettiMP, WellerE, HufdhiR, NovakP, et al. Distinct small intestine mast cell histologic changes in patients with hereditary alpha-tryptasemia and mast cell activation syndrome. Am J Surg Pathol. 2021;45(7):997-1004.
LeQT, LyonsJJ, NaranjoAN, OliveraA, LazarusRA, MetcalfeDD, et al. Impact of naturally forming human alpha/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia. J Exp Med. 2019;216(10):2348-61.
LyonsJJ. Hereditary alpha tryptasemia: genotyping and associated clinical features. Immunol Allergy Clin North Am. 2018;38(3):483-95.
LyonsJJ, ChovanecJ, O'ConnellMP, LiuY, SelbJ, ZanottiR, et al. Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol. 2021;147(2):622-32.
GreinerG, SprinzlB, GorskaA, RatzingerF, GurbiszM, WitzenederN, et al. Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood. 2021;137(2):238-47.